The Greatest Value Stock in Pharma — or a Trap Set by a Better Drug

Описание: Something is wrong with Novo Nordisk. The market says it's dying. The company just raised guidance.

In June 2026: a near-monopoly pharmaceutical franchise, trading at roughly 10x earnings — 61% below its own historical average — the same year its obesity franchise grew 31%. And a rival just reported the most impressive drug trial result in a generation.

So we rebuilt the documented methods of five of history's greatest investors and put Novo Nordisk (NYSE: NVO) on trial. We pulled the SEC filings to see where the real money moved. We measured how loud the crowd is. Three lenses — the coldest analysis we can give you. What the board found is the widest disagreement this show has recorded.

*THREE LENSES:*
*METHOD:* Five published frameworks, five scores, one composite
*MONEY:* Who among the world's 15 most-followed investors actually holds NVO — and what that says
*CROWD:* How hyped is this stock vs its pharma peers — and what that means for the price

*THE BOARD:*
John Templeton — the contrarian (maximum pessimism)
Philip Fisher — the growth pioneer (never buy the #2 in a technology race)
Benjamin Graham — the father of value (margin of safety)
Stanley Druckenmiller — the macro legend
Howard Marks — the second-level thinker

The fight: Eli Lilly reported Phase 3 results for retatrutide in June 2026. Average body weight loss: 28.3%. Bariatric-surgery territory, from a pill. Novo's drug achieves roughly half that. And yet Novo has the oral pill — Lilly's oral version is years away.

Same company, same day. The methods went to war. That fight is the whole episode.

*MONEY LENS:* 0 of the 15 living investing legends tracked own the US ADR. Note: Novo's primary listing is on Copenhagen (not all holdings visible in US 13F filings).
*CROWD LENS:* Crowd index 0.98x industry baseline — no hype premium. The crowd is not chasing this stock. That is information.

THE 3-LENS TRIANGULATION (this cut): after the board scores the METHOD, we follow the MONEY — how many of 15 living legends actually hold the stock (SEC 13F filings) — and the CROWD, on an animated Hype Meter (public attention vs its own industry). MONEY: 0 of 15 living legends hold the bargain. CROWD: 1.0× — no hype premium at all, the quietest tape in pharma. A presenter cold-open frames the promise: we judge this company in the coldest, most objective way we can, then hand you the tools to decide for yourself. NO verdict in the open.

CHAPTERS (~17:15 total)
0:00 Cold open — Novo Nordisk introduced
0:55 WHILE THE MARKET SOARED
2:32 THE NUMBERS
4:54 John Templeton — THE CONTRARIAN
6:27 Philip Fisher — THE GROWTH PIONEER
8:11 Benjamin Graham — THE FATHER OF VALUE
10:02 Stanley Druckenmiller — THE MACRO LEGEND
11:49 Howard Marks — THE SECOND-LEVEL THINKER
15:06 WHERE'S THE SMART MONEY?
16:01 THE HYPE METER
16:19 THE TELLS
16:40 WHICH LEGEND IS WRONG?
16:53 THE GREATS' PLAYBOOK

EDITORIAL NOTE: Every number checked against public filings and June 2026 reporting. Trailing P/E (~10.3x) verified. Lilly's retatrutide 28.3% from TRIUMPH-ONE Phase 3 (June 2026). Smart money 0/15 = no US 13F position confirmed; Copenhagen primary listing means many holdings are not reported in US 13F filings. Crowd index 0.98x = proprietary calculation (Wikipedia traffic + GDELT news, normalized to pharma sector baseline).

DISCLAIMER: This video is for education and entertainment only and is NOT financial advice. The "board" are AI models built from these investors' publicly published methods and principles — they are NOT the individuals, do NOT use their real quotes, and are NOT affiliated with or endorsed by them. Numbers are as of June 2026; the methods are timeless — rerun them with today's numbers. Do your own research.

#NovoNordisk #NVO #GLP1 #Ozempic #Wegovy #investing #stocks #valueinvesting #pharma #Lilly #retatrutide